These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 30082415)

  • 1. Behavioral Effect of Chemogenetic Inhibition Is Directly Related to Receptor Transduction Levels in Rhesus Monkeys.
    Upright NA; Brookshire SW; Schnebelen W; Damatac CG; Hof PR; Browning PGF; Croxson PL; Rudebeck PH; Baxter MG
    J Neurosci; 2018 Sep; 38(37):7969-7975. PubMed ID: 30082415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of chemogenetic actuator drugs on prefrontal cortex-dependent working memory in nonhuman primates.
    Upright NA; Baxter MG
    Neuropsychopharmacology; 2020 Oct; 45(11):1793-1798. PubMed ID: 32193513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of clozapine-N-oxide and compound 21 on sleep in laboratory mice.
    Traut J; Mengual JP; Meijer EJ; McKillop LE; Alfonsa H; Hoerder-Suabedissen A; Song SH; Fehér KD; Riemann D; Molnar Z; Akerman CJ; Vyazovskiy VV; Krone LB
    Elife; 2023 Mar; 12():. PubMed ID: 36892930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemogenetic enhancement of functional recovery after a sciatic nerve injury.
    Jaiswal PB; English AW
    Eur J Neurosci; 2017 May; 45(10):1252-1257. PubMed ID: 28244163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys.
    Nagai Y; Miyakawa N; Takuwa H; Hori Y; Oyama K; Ji B; Takahashi M; Huang XP; Slocum ST; DiBerto JF; Xiong Y; Urushihata T; Hirabayashi T; Fujimoto A; Mimura K; English JG; Liu J; Inoue KI; Kumata K; Seki C; Ono M; Shimojo M; Zhang MR; Tomita Y; Nakahara J; Suhara T; Takada M; Higuchi M; Jin J; Roth BL; Minamimoto T
    Nat Neurosci; 2020 Sep; 23(9):1157-1167. PubMed ID: 32632286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.
    Gomez JL; Bonaventura J; Lesniak W; Mathews WB; Sysa-Shah P; Rodriguez LA; Ellis RJ; Richie CT; Harvey BK; Dannals RF; Pomper MG; Bonci A; Michaelides M
    Science; 2017 Aug; 357(6350):503-507. PubMed ID: 28774929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ventral Tegmental Area Dopamine Cell Activation during Male Rat Sexual Behavior Regulates Neuroplasticity and d-Amphetamine Cross-Sensitization following Sex Abstinence.
    Beloate LN; Omrani A; Adan RA; Webb IC; Coolen LM
    J Neurosci; 2016 Sep; 36(38):9949-61. PubMed ID: 27656032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G
    Marciante AB; Farmer GE; Cunningham JT
    J Neurophysiol; 2020 Aug; 124(2):591-609. PubMed ID: 32697679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments.
    MacLaren DA; Browne RW; Shaw JK; Krishnan Radhakrishnan S; Khare P; España RA; Clark SD
    eNeuro; 2016; 3(5):. PubMed ID: 27822508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic Behavioral Manipulation via Orally Delivered Chemogenetic Actuator in Macaques.
    Oyama K; Hori Y; Nagai Y; Miyakawa N; Mimura K; Hirabayashi T; Inoue KI; Takada M; Higuchi M; Minamimoto T
    J Neurosci; 2022 Mar; 42(12):2552-2561. PubMed ID: 35110390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gi-DREADD Expression in Peripheral Nerves Produces Ligand-Dependent Analgesia, as well as Ligand-Independent Functional Changes in Sensory Neurons.
    Saloman JL; Scheff NN; Snyder LM; Ross SE; Davis BM; Gold MS
    J Neurosci; 2016 Oct; 36(42):10769-10781. PubMed ID: 27798132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo electrophysiological validation of DREADD-based modulation of pallidal neurons in the non-human primate.
    Deffains M; Nguyen TH; Orignac H; Biendon N; Dovero S; Bezard E; Boraud T
    Eur J Neurosci; 2021 Apr; 53(7):2192-2204. PubMed ID: 32306446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does chronic systemic injection of the DREADD agonists clozapine-N-oxide or Compound 21 change behavior relevant to locomotion, exploration, anxiety, and depression in male non-DREADD-expressing mice?
    Tran FH; Spears SL; Ahn KJ; Eisch AJ; Yun S
    Neurosci Lett; 2020 Nov; 739():135432. PubMed ID: 33080350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics.
    Raper J; Morrison RD; Daniels JS; Howell L; Bachevalier J; Wichmann T; Galvan A
    ACS Chem Neurosci; 2017 Jul; 8(7):1570-1576. PubMed ID: 28324647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of DREADD receptor expression and function in rhesus macaques trained to discriminate ethanol.
    Allen DC; Jimenez VA; Carlson TL; Walter NA; Grant KA; Cuzon Carlson VC
    Neuropsychopharmacology; 2022 Mar; 47(4):857-865. PubMed ID: 34654906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A head-to-head comparison of two DREADD agonists for suppressing operant behavior in rats via VTA dopamine neuron inhibition.
    Lawson KA; Ruiz CM; Mahler SV
    Psychopharmacology (Berl); 2023 Oct; 240(10):2101-2110. PubMed ID: 37530882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodal Imaging for DREADD-Expressing Neurons in Living Brain and Their Application to Implantation of iPSC-Derived Neural Progenitors.
    Ji B; Kaneko H; Minamimoto T; Inoue H; Takeuchi H; Kumata K; Zhang MR; Aoki I; Seki C; Ono M; Tokunaga M; Tsukamoto S; Tanabe K; Shin RM; Minamihisamatsu T; Kito S; Richmond BJ; Suhara T; Higuchi M
    J Neurosci; 2016 Nov; 36(45):11544-11558. PubMed ID: 27911758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CNO Administration Increases Dopamine and Glutamate in the Medial Prefrontal Cortex of Wistar Rats: Further Concerns for the Validity of the CNO-activated DREADD Procedure.
    Rodd ZA; Engleman EA; Truitt WA; Burke AR; Molosh AI; Bell RL; Hauser SR
    Neuroscience; 2022 May; 491():176-184. PubMed ID: 35351573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DREADD-induced activation of subfornical organ neurons stimulates thirst and salt appetite.
    Nation HL; Nicoleau M; Kinsman BJ; Browning KN; Stocker SD
    J Neurophysiol; 2016 Jun; 115(6):3123-9. PubMed ID: 27030736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.
    Chen X; Choo H; Huang XP; Yang X; Stone O; Roth BL; Jin J
    ACS Chem Neurosci; 2015 Mar; 6(3):476-84. PubMed ID: 25587888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.